Table 2.

Treatment emergent adverse events (all causalities)

Adverse event	Any grade, n (%)	Grade 3, n (%)	Grade 4, n (%)
CP-870,893 0.05 mg/kg (n = 5)
Abdominal pain	4 (80)	1 (20)	0
Back pain	2 (40)	0	0
Chills	4 (80)	0	0
Constipation	1 (20)	1 (20)	0
Dehydration	1 (20)	1 (20)	0
CP-870,893 0.1 mg/kg (n = 3)
Arthralgias	2 (67)	0	0
Autoimmune disorder	1 (33)	1 (33)	0
Dyspnea	2 (67)	0	0
Eye lid ptosis	1 (33)	1 (33)	0
Musculoskeletal pain	2 (67)	0	0
Nausea	2 (67)	0	0
Non-cardiac chest pain	1 (33)	1 (33)	0
CP-870,893 0.2 mg/kg (n = 13)
Abdominal distention	2 (15)	0	0
Abdominal pain	2 (15)	1 (8)	0
Arthralgias	3 (23)	0	0
AST increase	2 (15)	1 (8)	0
Bronchitis	2 (15)	0	0
Chills	3 (23)	0	0
Confusion	1 (8)	1 (8)	0
Constipation	3 (23)	0	0
Cough	4 (31)	0	0
Cytokine release syndrome	11 (85)	2 (16)*	0
Dehydration	2 (15)	0	0
Diarrhea	3 (23)	0	0
Dizziness	3 (23)	0	0
Dyspnea	2 (15)	1 (8)	0
Fatigue	7 (54)	1 (8)	0
Flushing	2 (15)	0	0
Headache	5 (39)	0	0
Hemoptysis	2 (15)	0	0
Hypophosphatemia	1 (8)	1 (8)	0
Lethargy	1 (8)	1 (8)	0
Lymphedema	1 (8)	1 (8)	0
Musculoskeletal chest pain	2 (15)	1 (8)	0
Nausea	5 (38)	0	0
Pleuritic pain	2 (15)	0	0
Pneumonia	1 (8)	1 (8)	0
Pulmonary embolism	1 (8)	0	1 (8)
Vomiting	3 (23)	0	0
CP-870,893 0.25 mg/kg (n = 6)
Alk Phos increase	3 (50)	1 (17)	0
ALT increase	3 (50)	0	0
AST increase	4 (67)	0	0
Anemia	2 (33)	0	0
Arthralgias	2 (33)	0	0
Back pain	3 (50)	1 (17)	0
Constipation	3 (50)	0	0
Cytokine release syndrome	4 (67)	1 (17)*	0
Dizziness	2 (33)	0	0
Dyspnea	2 (33)	0	0
Fatigue	2 (33)	0	0
Headache	2 (33)	0	0
LDH increase	1 (17)	1 (17)	0
Muscle weakness	2 (33)	1 (17)	0
Pyrexia	2 (33)	0	0
Upper respiratory tract infection	2 (33)	0	0
Urticaria	1 (17)	1 (17)*	0

Events listed if present in ≥ 2 for toxicities grade 1 and 2, or in ≥ 1 if grades 3 or 4 toxicity, *dose-limiting toxicity (DLT).